BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications

Transaction increases BioLineRx’s stake by 20%, to 80%, ahead of numerous potential value-creating milestones. Top-line results from ongoing Phase 2a pancreatic cancer study in combination with KEYTRUDA® expected this quarter.

October 3rd, 2018|Clinical Program BL8040, Recent News|

BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization

Data from first lead-in patient cohort prompts Data Monitoring Committee to recommend early continuation to randomized placebo-controlled part 2 of trial.

August 7th, 2018|Clinical Program BL8040, Recent News|

BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer

x30-50 patients in additional arm will be investigated under the collaboration. Results from combination of BL-8040 and KEYTRUDA® (pembrolizumab) in COMBAT/KEYNOTE-202 study will be reported in H2 2018 as planned.

July 30th, 2018|Clinical Program BL8040, Recent News|

BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation

BL-8040 was safe and well tolerated, and all transplanted recipients were successfully engrafted

May 17th, 2018|Clinical Program BL8040, Recent News|

BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications

BioLineRx Ltd. (NASDAQ/TASE: BLRX) today announced that it has entered into a collaboration with Genentech, a member of the Roche Group, to support several Phase 1b studies investigating BioLineRx’s BL-8040 in combination with Atezolizumab, Genentech’s anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of […]

September 7th, 2016|Clinical Program BL8040, Recent News|

BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML

BioLineRx (NASDAQ/TASE: BLRX) announced today positive top-line results from BL-8040’s Phase 2 clinical trial in relapsed or refractory acute myeloid leukemia . Data also identify a potential biomarker for future selection of BL-8040-responsive AML patients

March 29th, 2016|Clinical Program BL8040, Recent News|

BioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment

BioLineRx Ltd. (NASDAQ/TASE:BLRX) announced today the initiation of a Phase 2 trial for BL-8040 as a novel approach for the mobilization and collection of bone marrow stem cells from the peripheral blood circulation.

March 23rd, 2016|Clinical Program BL8040, Recent News|

BioLineRx Announces Collaboration with MSD to investigate the combination of KEYTRUDA® (pembrolizumab) and BL-8040 in Pancreatic Cancer

BioLineRx Ltd. (NASDAQ/TASE: BLRX) today announced a collaboration with MSD, known as Merck in the US and Canada, to support a Phase 2 study investigating BioLineRx’s BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in patients with metastatic pancreatic cancer.

January 12th, 2016|Clinical Program BL8040, Recent News|

Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions, hypoplastic myelodysplastic syndrome (hMDS) and aplastic anemia (AA) with BL8040

“BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions

Efficacy and safety study, in collaboration with MD Anderson Cancer Center,

will assess BL-8040 as combination treatment with immunosuppressants

Interim results of study, in patients with hypoplastic myelodysplastic

syndrome (hMDS) and aplastic anemia (AA), expected by end of 2016″

November 23rd, 2015|Clinical Program BL8040, Recent News|

Positive Clinical Results from First Part of Phase 2 Trial in r/r AML with BL8040

“BioLineRx Announces Positive Clinical Results from First Part of Phase 2 Trial in r/r AML

 

– Data strongly suggest BL-8040 has potent anti-leukemic activity

in combination with Ara-C in AML “-

November 5th, 2015|Clinical Program BL8040, Recent News|